Clinical Trials
2 trialsNCT03580655 2026-04-24
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT07255638 2026-04-20
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Blueprint Medicines Corporation
Recruiting